Eur J Clin Pharmacol:氢氯噻嗪的长期使用与皮肤和嘴唇鳞状细胞癌的发生有关

2022-08-03 MedSci原创 MedSci原创

皮肤鳞状细胞癌(CSCC)和唇鳞状细胞癌(lip SCC)都与紫外线辐射有很大关系其中一个主要的风险因素是使用光敏性药物,这些药物的代谢物能够吸收紫外线辐射,特别是在皮肤上。

皮肤鳞状细胞癌(CSCC)和唇鳞状细胞癌(lip SCC)都与紫外线辐射有很大关系其中一个主要的风险因素是使用光敏性药物,这些药物的代谢物能够吸收紫外线辐射,特别是在皮肤上。这些药物之一是氢氯噻嗪(HCTZ),这是一种属于噻嗪类利尿剂的抗高血压药,是控制心血管疾病的最常用处方药之一。有人认为长期使用HCTZ治疗全身性疾病有利于恶性皮肤病的发展,包括皮肤和嘴唇SCC。近日,发表于Eur J Clin Pharmacol的一项系统回顾和荟萃分析探究了使用HCTZ与皮肤和唇部SCC风险之间的关系。

研究人员对病例对照研究进行了系统回顾和meta分析。我们检索了Cochrane图书馆、PubMed、Scopus、Web of Science和LILACS。本研究在PROSPERO注册了CRD42019129710协议。荟萃分析是用Stata软件(12.0版)进行的。

 

结果,研究人员共检索了2181项提及该主题的已发表的研究,其中6项被纳入本系统回顾。分析结果显示,男性比女性更经常受到皮肤和嘴唇鳞状细胞癌的影响,比例为1.42:1。皮肤和嘴唇鳞状细胞癌发病的平均年龄为73.7岁。这项荟萃分析显示,使用氢氯噻嗪的人在身体任何区域发生皮肤和嘴唇鳞状细胞癌的机会比不使用的人高1.76倍。此外,在HCTZ使用者中,头颈部皮肤鳞状细胞癌的风险系数高出1.80(CI 95% = 1.71-1.89)。此外,在对使用剂量的分析中,当使用的HCTZ浓度低于50,000毫克时,患鳞状细胞癌的机会降低了3.37倍。

综上所述,该研究结果证实了使用氢氯噻嗪与皮肤和嘴唇鳞状细胞癌发展之间的关联。建议HCTZ使用者注意防护紫外线,并指导医疗委员会和公共当局监测这些使用者的重要性。

原始出处:

Ana Cláudia de Macedo Andrade, et al., Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis. Eur J Clin Pharmacol. 2022 Jun;78(6):919-930. doi: 10.1007/s00228-022-03299-x.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2023-06-05 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2023-03-23 fangcong
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1908726, encodeId=4fe11908e2652, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Oct 26 20:44:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996498, encodeId=6cd7199649861, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jun 05 21:44:16 CST 2023, time=2023-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788493, encodeId=df141e8849357, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Mar 26 08:44:16 CST 2023, time=2023-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010202, encodeId=3fce2010202b1, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat May 27 05:44:16 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787816, encodeId=18231e87816d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Nov 04 16:44:16 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643242, encodeId=17b116432429c, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Thu Mar 23 00:44:16 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979358, encodeId=b6fa19e9358eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed May 31 09:44:16 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360556, encodeId=65c21360556d2, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 01 01:44:16 CST 2022, time=2022-08-01, status=1, ipAttribution=)]

相关资讯

Nat Commun:VAV2促进皮肤和头颈部鳞状细胞癌的再生性增殖

皮肤鳞状细胞癌(cSCC)和头颈部鳞状细胞癌(hnSCC)是分别从皮肤的分层上皮和上消化道的粘膜内层发生的癌症。在全球范围内,由于其升高的发病率,高侵袭性,较差的疾病预后以及有限的治疗手段和效果,如今

Ann Oncol:派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤!

派姆单抗在局部晚期和复发性或转移性皮肤鳞状细胞癌患者中具有强大抗肿瘤活性

Eur J Cancer:Cemiplimab治疗局部晚期/转移性皮肤鳞状细胞癌的真实数据

Cemiplimab 治疗真实临床晚期 cSCC 患者的安全性和有效性结果与临床试验中获得的结果一致

Clin Cancer Res:抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性

抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性。

皮肤鳞状细胞癌,什么时候该切?什么时候不该切?Is a question.

外科手术:皮肤鳞状细胞癌的一线治疗。

Br J Dermatol:即使是皮肤鳞状细胞癌患者,也不可以的掉以轻心

大多数皮肤鳞状细胞癌(CSCC)可以通过手术成功切除,不需要进一步的研究或临床随访。然而,由于局部和远处转移的风险,应该考虑对一些患者进行更积极的干预和监测。